Nonadherence to Gleevec in GIST patients is common, with cognitive functioning, TDM, and social support as key indicators. A machine learning model using 64 covariates identified 19 significant ...

Continuous Gleevec treatment in GIST patients significantly prolongs progression-free survival and delays resistance compared to treatment interruption. Median progression-free survival was 6.1 months ...

FRIDAY, May 19, 2017 -- A leukemia drug might also effectively treat severe asthma, a small-scale clinical trial suggests. Gleevec (imatinib) reduced the "twitchiness" of airways, making them less ...

The generic manufacturer may try to maximize profits during the initial exclusivity period, says an expert from a leading health plan. Sun Pharmaceutical’s product Imatinib Mesylate, the generic ...

In a study of patients with chronic myeloid leukemia, some 95 percent have survived the cancer after five years due to treatment with Gleevec, according to results published this week in the New ...

Though enormously successful, the leukemia drug Gleevec has some downsides. Studies have linked the drug to heart failure in a small number of patients, and drug resistance can be a problem. But ...

- Clinical data showing unprecedented 89% reduction in risk of GIST relapse with use of Gleevec after surgery are basis for FDA, EMEA, Swissmedic filings EAST HANOVER, N.J., August 27, 2008 ...

Gleevec, the daily pill that turned a killer type of leukemia into a manageable disease, may also help slow the worsening of diabetes, researchers reported Monday. Subscribe to read this story ad-free ...

Add Yahoo as a preferred source to see more of our stories on Google. ZURICH (Reuters) - India's Sun Pharma (SUN.NS) launched a generic version of Novartis's (NOVN.VX) leukaemia drug Gleevec on Monday ...

Wonder drug Gleevec can keep cancer patients alive longer. But can it keep the costs down? Imatinib mesylate, commercially sold as Gleevec, has been found out to extend the lives of blood cancer ...

Many investors know Novartis (NVS 1.48%) for its robust dividend, a diversified business that ranges from vaccines to generic drugs, and the discovery of the revolutionary chronic myeloid leukemia, or ...

Add Yahoo as a preferred source to see more of our stories on Google. A man carrying a gas cylinder walks out of the research and development centre of Sun Pharmaceutical Industries Ltd in Mumbai May ...